Loading
Life sciences · Journal article
Bio-design and Manufacturing · September 16, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Anoikis presents an alternative scheme for suppressing tumor metastasis. While limited by off-target effects, rapid degradation, and reactive oxygen species (ROS) accumulation, anoikis resistance remains a persistent challenge for current tumor therapy. The use of external and endogenous stimuli to trigger ROS bursts, as well as chirality-enhanced tumor microenvironment (TME) penetration, offers a valid solution. We developed a stimuli-responsive nanoreactor by coupling chiral histidine-modified manganese ferrite (MnFe 2 O 4 -PEG) nanoparticles with chiral cysteine-modified black phosphorus (BP) nanosheets via an ROS-sensitive thioketal (TK) bond to form a MnFe 2 O 4 -BP chiral magnetic nanoreactor (CT-MFBP). L-MFBP exhibited superior cellular uptake and intracellular retention due to its enhanced affinity for cell membranes. After entering the TME, the thioketal bond was cleaved by alternating magnetic field (AMF)-induced ROS, leading to the decomposition of the nanoreactor into chiral BP components. Subsequently, ROS accumulation was further amplified using BP-mediated photodynamic therapy (PDT). In addition, the nanoreactor demonstrated catalase (CAT)-like activity, converting endogenous H 2 O 2 into O 2, thereby effectively alleviating the tumor hypoxic microenvironment and enhancing PDT efficacy. Furthermore, these events activated the mitogen-activated protein kinase (MAPK)-caspase 3 signaling pathway by upregulating p38 protein and Bcl-2-modifying factor (BMF) expression, which together promoted anoikis in tumor cells—a finding further validated by genomic analysis. Both in vitro and in vivo results confirmed that L-MFBP provides a robust regulatory strategy to induce anoikis and suppress tumor metastasis, offering a promising approach for chiral magnetic nanomedicine in clinical antitumor applications.